Primary prophylaxis with pegfilgrastim in patients with newly-diagnosed diffuse large B-cell lymphoma: propensity score and instrumental variable analyses. Issue 10 (23rd August 2020)

• Record Type: Journal Article
• Authors: Matsuda, Kensuke; Taisuke, Jo; Miyauchi, Masashi; Toyama, Kazuhiro; Nakazaki, Kumi; Matsui, Hiroki; Fushimi, Kiyohide; Yasunaga, Hideo; Kurokawa, Mineo
• Is Part Of: Leukemia & lymphoma. Volume 61:Issue 10(2020)
• Page Start: 2435
• Page End: 2441
• Publication Date: 2020-08-23
• Subjects: Pegfilgrastim -- filgrastim -- Febrile neutropenia -- malignant lymphoma -- propensity-matched analysis; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2020.1775207
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: The clinical impact of pegfilgrastim in day-to-day practice remains unclear. This study evaluated the effectiveness of pegfilgrastim compared with daily filgrastim in patients with DLBCL who received the first-cycle of R-CHOP treatment by using a Japanese national inpatient database. Patient characteristics were adjusted by using propensity-score matching and stabilized inverse probability of treatment weighting (IPTW). In 1295 propensity-score-matched pairs, the incidence of febrile neutropenia was significantly lower in the pegfilgrastim group (risk difference 6.1%, 95% CI 4.1%–8.1%) than in the filgrastim group. In the pegfilgrastim group, the length of hospital stay and the total costs were also significantly reduced (percent reduction 34% [95% CI: 31%–37%], percent reduction 12% [95% CI: 9%–15%], respectively). The stabilized IPTW showed comparable results. In day-to-day practice, the simple mode of pegfilgrastim administration may be advantageous.